EVALUATION OF HRQOL IN PATIENTS WITH CORONARY ARTERY DISEASE AFTER PCI
Main Article Content
Keywords
Coronary Artery Disease, Percutaneous Coronary Intervention, Quality of Life, MACE
Abstract
Background: The background of the study of Health-Related Quality of Life (HRQoL) in individuals who have undergone Percutaneous Coronary Intervention (PCI) for coronary artery disease is rooted in the intersection of cardiovascular medicine and patient-centered outcomes.
Methodology: A prospective observational study was carried out in the Cardiology Department of Vivekanandha Medical Care Hospital, Tamil Nadu over a span of six months. The cases were randomly assigned and Major adverse cardiac events (MACE) were evaluated in patients having Coronary Artery Disease (CAD) who underwent PCI. The health-related quality of life using the EQ-5D-5L questionnaire was assessed in CAD patients who underwent PCI. The study's results were comprehensively scrutinized, and the data were analyzed with the ANOVA using Graph Pad Prism 10.0.2.
Result: A total of 152 participants with valid monitoring person-day records were included. During the third visit, assessed the Patient's health-related quality of life using the EQ- 5D-5L questionnaire who underwent Percutaneous Coronary Intervention for Coronary Artery Disease. In Our study's findings, out of 112 patients MACE were evaluated which included (myocardial infarction, stroke, recurrent hospitalization, coronary revascularization, and death) and patient HRQOL was assessed. Conclusion: In this specific investigation, researchers utilized the EQ-5D-5L questionnaire as a systematic tool for gathering organized data on various aspects of patient well-being. The conclusion likely encapsulates the key findings related to the impact, or lack of PCI on the HRQoL in patients with CAD. This encompasses a comprehensive understanding of the influence of PCI on physical well-being and may provide insights into strategies for improvement.
References
2. Wang X-J, Li Q-P. The roles of mesenchymal stem cells (MSCs) therapy in ischemic heart diseases. Biochemical and biophysical research communications. 2007;359(2):189-93.
3. Matta AG, Nader V, Roncalli J. Management of myocardial infarction with Nonobstructive Coronary Arteries (MINOCA): a subset of acute coronary syndrome patients. Reviews in Cardiovascular Medicine. 2021;22(3):625-34.
4. Ferreira PL, Pereira LN, Antunes P, Ferreira LN. EQ-5D-5L Portuguese population norms. The European Journal of Health Economics. 2023:1-10.
5. Si J-H, Ma N, Gao F, Mo D-P, Luo G, Miao Z-R. Effect of a drug-eluting stent vs. Bare metal stent for the treatment of symptomatic intracranial and vertebral artery stenosis. Frontiers in Neurology. 2022;13:854226.
6. Franey EG, Kritz-Silverstein D, Richard EL, Alcaraz JE, Nievergelt CM, Shaffer RA, et al. Association of race and major adverse cardiac events (mace): the atherosclerosis risk in communities (aric) cohort. Journal of Aging Research. 2020;2020.
7. Chien L-N, Chen C-C, Chang Y-H, Yu F-C, Tsai C-T, Liu H-Y, et al. Risk of Heart Failure in Patients with ST-Elevation Myocardial Infarction Receiving Drug-Eluting Stent Implantation and Undefined Duration of Antiplatelets. Journal of Personalized Medicine. 2022;12(3):369.
8. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Journal of the American college of cardiology. 2004;44(3):E1- E211.
9. Bibi S, Khan A, Khan AH, Khan MN, Mushtaq S, Rashid SA. Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents. Frontiers in pharmacology. 2022;13:900798.
10. Ahmed T, Pacha HM, Addoumieh A, Koutroumpakis E, Song J, Charitakis K, et al. Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents. Frontiers in Cardiovascular Medicine. 2022;9:901431.
11. John JE, Claggett B, Skali H, Solomon SD, Cunningham JW, Matsushita K, et al. Coronary artery disease and heart failure with preserved ejection fraction: the ARIC study. Journal of the American Heart Association. 2022;11(17):e021660.
12. Gao Z, Wang P, Hong J, Yan Y, Tong T, Wu B, et al. Health-related quality of life among Chinese patients with Crohn’s disease: a cross-sectional survey using the EQ-5D-5L. Health and Quality of Life Outcomes. 2022;20(1):1-9.
13. Zeng M, Yan X, Wu W. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis. BMC cardiovascular disorders. 2021;21:1-9.
14. Lee H, Son Y-J. Influence of smoking status on risk of incident heart failure: a systematic review and meta-analysis of prospective cohort studies. International journal of environmental research and public health. 2019;16(15):2697.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Mala Mahalakshmi J
Department of General Medicine, Sree Balaji Medical College and Hospital, Chennai, Tamilnadu, India
Shrijaa P
Department of General Medicine, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry, India.
Priyadharshini. P
Department of Pharmacy Practice, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamilnadu, India.
Priyadharshini. A
Department of Pharmacy Practice, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamilnadu, India.
Parwin Banu M
Department of Pharmacy Practice, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamilnadu, India.
Panneerselvam Theivendren
Department of Pharmaceutical Chemistry, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamilnadu, India
Shangavi. V
Department of Pharmacy Practice, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamilnadu, India.